NBIXClinical Trials•prnewswire•
Neurocrine Biosciences to Present New Data from Phase 2 Study of Osavampator in Adults with Major Depressive Disorder at 38th Annual Psych Congress 2025
Sentiment:Neutral (60)
Summary
(NASDAQ:NBIX) Additional Data from SAVITRI™ Study Expand on Top-Line Results Announced in April 2024 SAVITRI Poster Presentation Chosen as Finalist for Psych Congress Poster Awards SAN DIEGO, Sept. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 16, 2025 by prnewswire